Tag Archive | "Cephalon"

Top 50 Pharma (top pharmaceutical companies)

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,


The term 'top pharma' can relate to the top pharmaceutical companies or the top 10 or 50... Read the full story

Partnering Agreements with Cephalon

Tags: , , , , , ,


This report provides all the information you require to better understand Cephalon and its partnering interests and activities over the past seven years. Read the full story

Cephalon: Company Profile

Tags: ,


Cephalon, Inc. is an indirect wholly owned subsidiary of Teva Pharmaceutical Industries Ltd, is , is reviewed in terms of partnering, licensing and M&A interests and activity over recent years Read the full story

Acino to acquire Cephalon’s Middle East and North Africa business

Tags: , , ,


Acino will acquire Cephalon’s combined Middle East and African business for a total consideration of approximately EUR 80 million. Read the full story

Cephalon to pay Teva $275m if deal cancelled

Tags: , , ,


Teva states in a notice to the US Securities and Exchange Commission (SEC) that if Cephalon cancels its acquisition by Teva, it will pay a fine of 4% of the $6.8 billion deal - or $275 million. Read the full story

Teva outbids Valeant to acquire Cephalon

Tags: , , ,


Cephalon have accepted a bid from Teva which values the company at $6.8 billion, some $1.1 billion more than the Valeant offer of several weeks ago. Read the full story

Valeant moves on to new M&A targets

Tags: , ,


Now that Teva Pharmaceutical Industries has snatched Cephalon, what's next for would-be suitor Valeant Pharmaceuticals? Read the full story

Acquisition agreement for Cephalon

Tags: , , ,


Definitive agreement under which Teva will acquire all of the outstanding shares of Cephalon for $81.50 per share in cash, or a total enterprise value of approximately $6.8 billion Read the full story

Current Agreements Deals Update – April 2011

Tags: , , , , , , , , , , ,


Welcome to the April 2011 edition of Current Agreements Deals Update. Read the full story

Valeant bid re-focusses pharma M&A interest

Tags: ,


Valeant Pharmaceuticals' $5.7 billion bid for Cephalon may spawn a series of copycat deals, Reuters reports... Read the full story